Financials

Discussions Technicals Seasonals

6709 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to ADVAGENE BIOPHARMA CO LTD operating, investing, and financing activities

6709 free cash flow for H1 24 is -27.72 M TWD. For 2023, 6709 free cash flow was -78.01 M TWD and operating cash flow was -78.01 M TWD.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: TWD

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—